Treatment of Guillain-Barré syndrome with high-dose intravenous immunoglobulins--a comparison with plasma exchange
Kamei, T.; Nakagawa, H.; Uchiyama, F.; Fukuyama, J.
Rinsho Shinkeigaku 33(6): 660-662
1993
ISSN/ISBN: 0009-918X PMID: 8403689 Document Number: 409827
We used high-dose intravenous immunoglobulin (IVIG) in the treatment of Guillain-Barré syndrome (GBS) and compared its therapeutic effects with those who were treated by plasma exchange (PE). For this study, we selected patients who had been within seven days from the onset and unable to walk without support at that time. Four patients (3 male, 1 female, mean age 41.8) were treated by plasma exchange with 3,000-4,000 ml exchange of plasma/day for 4-6 days. Other four patients (2 male, 2 female, mean age 45.7) were treated with intravenous high-dose immunoglobulin: 400 mg/kg/day for 3-5 days. The functional scale was measured at study entry and after the treatment daily. The mean times to the recovery of independent walk (a functional grade 2) were 23.8 and 10.0 days for PE and IVIG respectively. Although there was a difference of disease severity between these two groups, IVIG was at least as effective as PE in the treatment of GBS.